Crispr Therapeutics AG
USPTO PatentsView assignee record - 77 granted patents across 7 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).
The verdict
According to USPTO PatentsView, Crispr ranks #4,554 of 49,997 tracked US assignees by granted-patent volume, with 77 patents across 7 technology areas.
- #4,554
- of 49,997 US assignees by volume
- Top 26%
- by Innovation Score (44.4/100)
- 19.0
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R4554 · Foreign Corporation #4,554 · 77 grants
GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-SMALL 77 grants
- TOP-DECILE #4,554/49,997
- PHOTO-FINISH Augustine Biomedical…
- CPC-NARROW C12N · 7 areas
- INNOV-PAR 44.4/100
- CLAIMS-RICH 19.0 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2020–2025 · 6y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Augustine Biomedical + Design, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Crispr’s 44.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Crispr
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Crispr Therapeutics · this assignee
Crispr Therapeutics · this assignee
44 score
- Elenion · near
Elenion · near
44 score
- NantBio · near
NantBio · near
44 score
- National Chain · near
National Chain · near
44 score
- Sunnybrook Health… · near
Sunnybrook Health… · near
44 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Crispr's Innovation Score is 44.4/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Crispr?
Each dot is one of Crispr’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Crispr’s own 19.0 claims/patent is ABOVE the 17.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Crispr's grants concentrate
Crispr Therapeutics AG is a focused PatentsView assignee: 7 CPC subclasses with 97.4% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (21 grants) versus a trough of 6 in 2020. By volume, Crispr sits between Augustine Biomedical + Design, LLC and Dong-eui University Industry-academic Cooperation Foundation.
Crispr's three-year grant acceleration
From 2019–2021 to 2022–2024, Crispr Therapeutics AG moved from 27 to 35 grants (1.30x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.
Who files at Crispr's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Augustine Biomedi…
Augustine Biomedical + Design, LLC
77 patents
- Bizerba SE & KG
Bizerba SE & Co. KG
77 patents
- Berlin Heart
Berlin Heart GmbH
77 patents
- Chep Technology P…
Chep Technology Pty Limited
77 patents
- Camso
Camso Inc.
77 patents
- Cardiovascular Sy…
Cardiovascular Systems, Inc.
77 patents
- Credo Technology…
Credo Technology Group Limited
77 patents
- Dong-eui Universi…
Dong-eui University Industry-academic Cooperation Foundation
77 patents
- Crispr Therapeuti… ◀
Crispr Therapeutics AG
77 patents
What this shows Crispr holds 77 patents at rank #4,551, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Crispr
By rank, the assignees closest to #4,551 in granted patent volume.
- Augustine Biomedical + Design, LLC #4,547 · 77 patents
- Bizerba SE & Co. KG #4,548 · 77 patents
- Berlin Heart GmbH #4,549 · 77 patents
- Chep Technology Pty Limited #4,550 · 77 patents
- Camso Inc. #4,552 · 77 patents
- Cardiovascular Systems, Inc. #4,553 · 77 patents
- Credo Technology Group Limited #4,554 · 77 patents
- Dong-eui University Industry-academic Cooperation Foundation #4,555 · 77 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Crispr's primary technology class.
- Monsanto Technology LLC 1,335 in class
- The Regents of the University of California 1,161 in class
- Novozymes A/S 656 in class
- Immatics Biotechnologies GmbH 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President and Fellows of Harvard College 594 in class
- Massachusetts Institute of Technology 541 in class
- The Trustees of the University of Pennsylvania 537 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Crispr, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Crispr ranks #132 of 4,144 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (44 here).
Similar claim depth
Nearest assignees by average claims per patent (19.0 here).
Crispr's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
44 Top 26% higher than 74% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 6 | 7.8% |
| 2021 | 21 | 27.3% |
| 2022 | 12 | 15.6% |
| 2023 | 14 | 18.2% |
| 2024 | 9 | 11.7% |
| 2025partial year | 15 | 19.5% |
Which technologies does Crispr Therapeutics AG patent most?
Top 7 of 7 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Crispr Therapeutics AG's patent record in context - here's where to go next.
- Crispr Therapeutics AG's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 97.4% of its portfolio - see every assignee active in that class. Explore C12N
- Ranked #4,554 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Crispr Therapeutics AG against Augustine Biomedical + Design, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 44.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.